Economic Evaluation of New MDR TB Regimens

NCT04207112 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Multi-drug Resistant Tuberculosis
Extensively Drug-Resistant Tuberculosis
Pulmonary Tuberculoses

Interventions

DRUG: Bedaquiline
DRUG: Pretomanid
DRUG: Moxifloxacin
DRUG: Linezolid
DRUG: Clofazimine
DRUG: Standard Drugs

Sponsor

Medecins Sans Frontieres, Netherlands

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]